Study of FK463 in the Treatment of Candidemia or Invasive Candidiasis
This study has been completed.
Sponsor:
Astellas Pharma Inc
Information provided by:
Astellas Pharma Inc
ClinicalTrials.gov Identifier:
NCT00036179
First received: May 8, 2002
Last updated: July 9, 2008
Last verified: July 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of the study is to evaluate the safety and efficacy of FK463 in the treatment of patients with confirmed candidemia or invasive candidiasis.
| Condition | Intervention | Phase |
|---|---|---|
|
Candidiasis |
Drug: FK463 |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | An Open-Label, Non-Comparative Study of FK463 in the Treatment of Candidemia or Invasive Candidiasis |
Resource links provided by NLM:
Further study details as provided by Astellas Pharma Inc:
| Enrollment: | 75 |
| Study Start Date: | February 1999 |
| Study Completion Date: | December 2002 |
| Primary Completion Date: | December 2002 (Final data collection date for primary outcome measure) |
This will be an open-label, non-comparative study of intravenous FK463. Enrollment will include at least 100 patients evaluable for efficacy.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria
- Has Candidemia or invasive candidiasis documented by typical clinical signs and symptoms and confirmed by fungal culture or histologic confirmation
Exclusion Criteria
- Has abnormal liver test parameters, e.g., AST or ALT > 10 times upper limit of normal
- Has life expectancy judged to be less than 5 days
- De novo patients who have received a systemic antifungal agent for the treatment of this episode of candidemia or invasive candidiasis for more than 48 hours prior to the first dose of FK463; or efficacy failure patients who have received =< 5 days of prior systemic antifungal therapy for the treatment of this episode of candidemia or invasive candidiasis
- Require treatment with topical or systemic antifungal agents for conditions other than candidemia or invasive candidiasis
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00036179
Locations
| Austria | |
| Medizinische Univ.-Klinik | |
| Graz, Austria, A 8036 | |
| Krankenhaus Elisabethinen Linz | |
| Linz, Austria, A-4010 | |
| France | |
| Hopital Henri Mondor, Dervice d'Hematologie Clinique | |
| Creteil, France, 94010 | |
| Hotel Dieu, Service d"Hematologie | |
| Nantes, France, 44093 | |
| Hopital Saint Louis, Service D'Hematologie/Greffe de Moelle | |
| Paris, France, 10 | |
| Hopital Necker Enfants Malades, Service d"Hematologie | |
| Paris, France, 75015 | |
| Germany | |
| Johann Wolfgang Goethe Universitat, Medizinische Klinik III | |
| Frankfurt, Germany, D-60590 | |
| Westpfalz Krankenhaus | |
| Kaiserslautern, Germany, D-67655 | |
| Medizinische Klinik und Poliklinik II, Abt. Hamatologie und Onkologie | |
| Leipzig, Germany, D-04103 | |
| Klinikum der Stadt, Medizinische Klinik A | |
| Ludwigshafen, Germany, D-67063 | |
| Uniklinik Mainz, III. Medizinische Klinik | |
| Mainz, Germany, 55101 | |
| LMU Munchen, Hamatopoetische Zell - Transplantation | |
| Munchen, Germany, D-81366 | |
| Universitat Wurzburg, Institut fur Molekulare und Infectionsbiologie | |
| Wurzburg, Germany, D-97070 | |
| Italy | |
| Nationale Institute for Cancer Research | |
| Genova, Italy, I 16132 | |
| Ospedale Niguarda-Ca Granda, Dept. of Internal Medicine Padiglione Brera | |
| Milano, Italy, 20162 | |
| Poland | |
| Institute of Haematology and Blood Transfusion | |
| Warsaw, Poland, 00-957 | |
| Spain | |
| Hospital Clinic I Provencial, Servicio Enfermadades Infecciosas | |
| Barcelona, Spain, 28041 | |
| Hospital Doce de Octubre, Servicio de Microbiologia Y Enfermadades Infecciosas | |
| Madrid, Spain, ES 28041 | |
| Hospital Gregorio Maranon, Servicio de Enfermadades Infecciosas | |
| Madrid, Spain, ES 28007 | |
| Sweden | |
| Huddinge University Hospital, Dept. of Transplantation Surgery/Immunology | |
| Huddinge, Sweden, SE141 86 | |
| United Kingdom | |
| Royal Free Hospital, Dept. of Haematological Oncology | |
| London, United Kingdom, NW3 2QG | |
| Christie Hospital NHS Trust | |
| Manchester, United Kingdom, M20 4BX | |
| Royal Marsden Hospital | |
| Sutton Surrey, United Kingdom, SM2 5PT | |
Sponsors and Collaborators
Astellas Pharma Inc
More Information
No publications provided
| Responsible Party: | Disclosure Office Europe, Astellas Pharma Europe BV |
| ClinicalTrials.gov Identifier: | NCT00036179 History of Changes |
| Other Study ID Numbers: | FG463-21-02, 98-0-047 |
| Study First Received: | May 8, 2002 |
| Last Updated: | July 9, 2008 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Astellas Pharma Inc:
|
Candidemia Anti-Fungal |
Additional relevant MeSH terms:
|
Candidiasis Candidemia Candidiasis, Invasive Mycoses Fungemia Sepsis Infection Systemic Inflammatory Response Syndrome |
Inflammation Pathologic Processes Micafungin Antifungal Agents Anti-Infective Agents Therapeutic Uses Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 19, 2013